Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial.
Caffeine
Clinical trial
Coffee
Non-alcoholic fatty liver disease
Type 2 diabetes
chlorogenic acid
Journal
Nutrition journal
ISSN: 1475-2891
Titre abrégé: Nutr J
Pays: England
ID NLM: 101152213
Informations de publication
Date de publication:
10 04 2021
10 04 2021
Historique:
received:
22
07
2020
accepted:
03
04
2021
entrez:
11
4
2021
pubmed:
12
4
2021
medline:
30
9
2021
Statut:
epublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is much more frequent and more severe, including cirrhosis, hepatocellular carcinoma in patients with type 2 diabetes. Coffee is a complex beverage with hundreds of compounds whereas caffeine and chlorogenic acid are the most abundant bioactive compounds. The published epidemiological data demonstrating beneficial associations between all categories of coffee exposure and ranges of liver outcomes are rapidly growing; however, the main contributors and cause-effect relationships have not yet been elucidated. To address existing knowledge gaps, we sought to determine the efficacy and safety of 6 months chlorogenic acid and/or caffeine supplementation in patients with type 2 diabetes affected by NAFLD. This trial was carried out at two Diabetes Centers to assess the effects of supplementation with daily doses of 200 mg chlorogenic acid, 200 mg caffeine, 200 mg chlorogenic acid plus 200 mg caffeine or placebo (starch) in patients with type 2 diabetes and NAFLD. The primary endpoint was reduction of hepatic fat and stiffness measured by FibroScan, and changes in serum hepatic enzymes and cytokeratin - 18 (CK-18) levels. Secondary endpoints were improvements in metabolic (including fasting glucose, homeostasis model assessment-estimated insulin resistance (HOMA-IR), hemoglobin A1c (HBA1C), C-peptide, insulin and lipid profiles) and inflammatory (including nuclear factor k-B (NF-KB), tumor necrosis factor (TNF-α), high sensitive- C reactive protein(hs-CRP)) parameters from baseline to the end of treatment. Neither chlorogenic acid nor caffeine was superior to placebo in attenuation of the hepatic fat and stiffness and other hepatic outcomes in patients with diabetes and NAFLD. Except for the lower level of total cholesterol in caffeine group (p = 0.04), and higher level of insulin in chlorogenic acid plus caffeine group (p = 0.01) compared with placebo, there were no significant differences among the treatment groups. These findings do not recommend caffeine and/or chlorogenic acid to treat NAFLD in type 2 diabetes patients. IRCT201707024010N21 . Registered 14 September 2017.
Sections du résumé
BACKGROUND
Non-alcoholic fatty liver disease (NAFLD) is much more frequent and more severe, including cirrhosis, hepatocellular carcinoma in patients with type 2 diabetes. Coffee is a complex beverage with hundreds of compounds whereas caffeine and chlorogenic acid are the most abundant bioactive compounds. The published epidemiological data demonstrating beneficial associations between all categories of coffee exposure and ranges of liver outcomes are rapidly growing; however, the main contributors and cause-effect relationships have not yet been elucidated. To address existing knowledge gaps, we sought to determine the efficacy and safety of 6 months chlorogenic acid and/or caffeine supplementation in patients with type 2 diabetes affected by NAFLD.
METHODS
This trial was carried out at two Diabetes Centers to assess the effects of supplementation with daily doses of 200 mg chlorogenic acid, 200 mg caffeine, 200 mg chlorogenic acid plus 200 mg caffeine or placebo (starch) in patients with type 2 diabetes and NAFLD. The primary endpoint was reduction of hepatic fat and stiffness measured by FibroScan, and changes in serum hepatic enzymes and cytokeratin - 18 (CK-18) levels. Secondary endpoints were improvements in metabolic (including fasting glucose, homeostasis model assessment-estimated insulin resistance (HOMA-IR), hemoglobin A1c (HBA1C), C-peptide, insulin and lipid profiles) and inflammatory (including nuclear factor k-B (NF-KB), tumor necrosis factor (TNF-α), high sensitive- C reactive protein(hs-CRP)) parameters from baseline to the end of treatment.
RESULTS
Neither chlorogenic acid nor caffeine was superior to placebo in attenuation of the hepatic fat and stiffness and other hepatic outcomes in patients with diabetes and NAFLD. Except for the lower level of total cholesterol in caffeine group (p = 0.04), and higher level of insulin in chlorogenic acid plus caffeine group (p = 0.01) compared with placebo, there were no significant differences among the treatment groups.
CONCLUSION
These findings do not recommend caffeine and/or chlorogenic acid to treat NAFLD in type 2 diabetes patients.
TRIAL REGISTRATION
IRCT201707024010N21 . Registered 14 September 2017.
Identifiants
pubmed: 33838673
doi: 10.1186/s12937-021-00694-5
pii: 10.1186/s12937-021-00694-5
pmc: PMC8037901
doi:
Substances chimiques
Coffee
0
Chlorogenic Acid
318ADP12RI
Caffeine
3G6A5W338E
Banques de données
IRCT
['IRCT201707024010N21']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
35Références
Gastroenterology. 2015 Jan;148(1):118-25; quiz e15
pubmed: 25305507
Diabetes Care. 2008 Mar;31(3):504-7
pubmed: 18070989
J Hum Hypertens. 2018 Feb;32(2):83-93
pubmed: 29302055
Nutr J. 2011 Sep 13;10:93
pubmed: 21914162
Am J Clin Nutr. 2014 Mar;99(3):535-42
pubmed: 24401715
BMJ. 2017 Nov 22;359:j5024
pubmed: 29167102
Nutrients. 2018 Jan 15;10(1):
pubmed: 29342916
Biosci Biotechnol Biochem. 2005 Nov;69(11):2219-23
pubmed: 16306706
Eur J Clin Nutr. 1995 Oct;49(10):779-84
pubmed: 8536656
Int J Epidemiol. 1996 Jun;25(3):513-20
pubmed: 8671551
Aliment Pharmacol Ther. 2012 Jan;35(1):76-82
pubmed: 22059453
Diabetes Care. 2018 Feb;41(2):372-382
pubmed: 29358469
Eur J Nutr. 2016 Oct;55(7):2221-30
pubmed: 26342706
Plant Foods Hum Nutr. 2013 Sep;68(3):268-73
pubmed: 23780748
Am J Clin Nutr. 2011 Jun;93(6):1212-9
pubmed: 21450934
Int J Food Sci Nutr. 2018 Dec;69(8):1003-1012
pubmed: 29513118
Am J Clin Nutr. 2010 Apr;91(4):950-7
pubmed: 20181814
PLoS One. 2014 Mar 28;9(3):e92482
pubmed: 24682220
Therap Adv Gastroenterol. 2016 May;9(3):417-8
pubmed: 27134669
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
BMJ Open. 2017 May 9;7(5):e013739
pubmed: 28490552
J Gastroenterol Hepatol. 2014 Mar;29(3):435-41
pubmed: 24199670
Nutrition. 2013 Jul-Aug;29(7-8):977-81
pubmed: 23510568
Am J Epidemiol. 2001 Feb 15;153(4):353-62
pubmed: 11207153
Eur J Nutr. 2019 Feb;58(1):271-280
pubmed: 29222637
J Tradit Complement Med. 2018 May 03;9(3):184-191
pubmed: 31193893
Hepatology. 2014 Aug;60(2):464-7
pubmed: 24464631
J Hypertens. 2012 Dec;30(12):2245-54
pubmed: 23032138
Eur J Gastroenterol Hepatol. 2017 Feb;29(2):e8-e12
pubmed: 27824642
Eur J Clin Nutr. 2012 Aug;66(8):872-7
pubmed: 22713771
Nutr Diabetes. 2014 Jun 30;4:e123
pubmed: 24979152
Nutr J. 2016 Dec 28;15(1):103
pubmed: 28031026
Int J Epidemiol. 1984 Dec;13(4):422-7
pubmed: 6519879
J Clin Epidemiol. 1995 Oct;48(10):1189-96
pubmed: 7561980
Metabolism. 2007 Dec;56(12):1694-8
pubmed: 17998023
FASEB J. 2003 Feb;17(2):301-3
pubmed: 12475892
Liver Int. 2014 Sep;34(8):1250-8
pubmed: 24267865
Nutr J. 2011 Jun 02;10:61
pubmed: 21631956
Ann Hepatol. 2021 Jan-Feb;20:100254
pubmed: 32920163
PLoS One. 2015 May 06;10(5):e0126550
pubmed: 25946046
Therap Adv Gastroenterol. 2016 Jan;9(1):113-20
pubmed: 26770272
Diabetes Care. 2014 Feb;37(2):569-86
pubmed: 24459154
J Nutr. 2016 Mar;146(3):524-31
pubmed: 26843588
Clin Nutr. 2019 Dec;38(6):2552-2557
pubmed: 30573353
Clin Nutr. 2016 Dec;35(6):1269-1281
pubmed: 27060021
J Hypertens. 2005 May;23(5):921-8
pubmed: 15834273
Biochemistry (Mosc). 2004 Jan;69(1):70-4
pubmed: 14972021
Diabetes Care. 2004 Dec;27(12):2990-2
pubmed: 15562223
Crit Rev Food Sci Nutr. 2019;59(4):652-663
pubmed: 28967799